Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Over the past decade, echinocandins have emerged as first-line antifungal agents for many Candida infections. The echinocandins have a unique mechanism of action, inhibiting the synthesis of β-1,3-d-glucan polymers, key components of the cell wall in pathogenic fungi. Caspofungin was the first echinocandin antifungal agent to become licensed for use. The objectives of this review are to summarize the existing published data on caspofungin, under the subject headings of chemistry and mechanism of action, spectrum of activity, pharmacodynamics, pharmacokinetics, clinical studies, safety, drug interactions, dosing, and an overview of the drug's current place in therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917 · cited 1×
“Adult patients qualified for study inclusion if they had evidence of proven or probable invasive aspergillosis, according to the modified European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria (De Pauw et al., 2008).”
MethodSelf-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 8×
“Clinical studies Invasive candidiasis and esophageal candidiasis Candida bloodstream infection, the fourth most common cause of nosocomial bloodstream infections in the United States, has contributed to rising healthcare costs and adversely affects patient outcomes (Pappas et al., 2009).”
BackgroundInfluentialComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217 · cited 4×
“The European Society for Clinical Microbiology and Infectious Diseases (ESCMID) strongly recommended (class A rating) the echinocandins for candidemia in non-neutropenic patients (Cornely et al., 2012) and patients with hematologic cancer or hematopoietic stem cell transplants (Ullman et al.”
BackgroundInfluentialResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Douglas, C. M., Foor, F., Marrinan, J. A., Morin, N., Nielsen, J. B., Dahl, A. M., Mazur, P., Baginsky, W., Li, W., & el-Sherbeini, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12907 · Cited by 401
Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12040 · Cited by 360
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Fungal ß(1,3)-D-glucan synthesis
Douglas, C. M. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.55.66 · Cited by 312 · cited 1×
“The cell-wall enzyme complex b-1,3-D-glucan synthase represents the target of caspofungin and other echinocandins (Douglas, 2001).”
Background
Cited by
Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring
Wang, Y., Beekman, J., Hew, J., Jackson, S., Issler-Fisher, A. C., Parungao, R., Lajevardi, S. S., Li, Z., & Maitz, P. K. M. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.018 · Cited by 696
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418
“This blockage causes a decrease in the incorporation of glucose monomers linking β-1,3 and β-1,6 glucans, thereby weakening the cell wall and leading to fungal cell lysis (Kathiravan et al., 2012; Song and Stevens, 2016).”
BackgroundHasim, S., & Coleman, J. J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0465 · Cited by 144
Moreno-Velásquez, S. D., Seidel, C., Juvvadi, P. R., Steinbach, W. J., & Read, N. D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00710-17 · Cited by 57
“-1,3-glucan in the cell wall, displaying what has been described as fungistatic activity against filamentous fungi (7), including A.”
BackgroundTranscriptional and translational landscape of Candida auris in response to caspofungin
Zamith-Miranda, D., Amatuzzi, R. F., Munhoz da Rocha, I. F., Martins, S. T., Lucena, A. C. R., Vieira, A. Z., Trentin, G., Almeida, F., Rodrigues, M. L., Nakayasu, E. S., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.007 · Cited by 29
Metadata
- Authors
- Song, J. C., & Stevens, D. A.
- Venue
- Critical Reviews in Microbiology
- Publisher
- Informa UK Limited
- Published
- 2015-09-15
- Volume
- 42
- Issue
- 5
- Pages
- 813-846
- ISSN
- 1040-841X (ISSN-L)
- 1549-7828
- OpenAlex
- W2219805094
- Cited by
- 61
- References
- 38
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes. https://app.cochat.ai/papers/10.3109/1040841x.2015.1068271
- The paper
- Song, J. C., & Stevens, D. A. (2016). Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes. Critical Reviews in Microbiology. https://doi.org/10.3109/1040841x.2015.1068271
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.